GHK-Cu dosage: topical concentrations versus the unvalidated injection

Ask how to dose GHK-Cu and the honest answer depends entirely on one word: route. The copper tripeptide glycyl-L-histidyl-L-lysine has a real, decades-long record as a topical cosmetic ingredient, applied to skin at defined concentrations.^[1] The injectable “peptide therapy” version that circulates in research-chemical circles is a different animal: no approved product, no validated dose, and almost no human safety data. This page keeps those two worlds separate, because conflating them is where people get hurt.

Why there is no “official” GHK-Cu dose

GHK was first isolated from human plasma and binds copper with high affinity to form the GHK-Cu complex studied for tissue remodeling.^[2] But it has never been through the drug-approval pipeline as an injectable medicine. That means no manufacturer label, no dose-finding trials in people, and no titration schedule a regulator has signed off on. Any number you see for injected GHK-Cu is convention borrowed from forums, not a clinically established dose. For what the molecule has and has not been shown to do, start with the GHK-Cu evidence review.

The topical route: where the concentrations are actually studied

The strongest human-relevant use is on the skin. As cosmetic copper tripeptide-1, GHK-Cu appears in creams and serums, and the literature describing its skin-regeneration actions discusses it as a leave-on cosmetic agent rather than an injected drug.^[1] Commercial formulations typically sit in the low range — often cited around one to a few tenths of a percent — applied once or twice daily to clean skin. The plausible benefits here are cosmetic and modest: supporting the collagen and repair machinery the peptide influences in laboratory models.^[1][3] This is the lane with the most evidence behind it, and the lowest risk.

The injected route: ranges people use, and why they are unvalidated

Subcutaneous GHK-Cu is sold and discussed in the peptide community, and the figures traded around are small — commonly framed as a couple of milligrams reconstituted and injected daily for short cycles. It is worth being blunt about what that number is: a community convention, not a finding. There is no published human trial that established a safe or effective injected dose, the regenerative claims rest on cell and animal work, and the gene-expression data that excite proponents come from laboratory systems, not dosed humans.^[4] Treating a borrowed forum figure as if it were a prescription is the core error here.

The copper problem that makes systemic use riskier

The peptide’s defining feature — that it carries copper — is exactly what raises the stakes when you put it under the skin rather than on it. Copper is an essential trace metal, but the body keeps it on a tight leash, and excess copper is genuinely toxic: it drives oxidative and metal-stress damage and disrupts related metal systems, as the biology of copper-overload states makes clear.^[5] A cream delivers a tiny, surface-limited amount; repeated injection bypasses that buffer entirely. Without monitoring, there is no feedback telling you whether you are nudging your copper load in the wrong direction. That asymmetry — cheap to apply, costly to misjudge — is the reason unsupervised systemic use is hard to justify.

Reconstitution: arithmetic, not endorsement

If injectable GHK-Cu lyophilized powder is involved, the powder is dissolved in bacteriostatic water before any dose is drawn. The amount of water you add sets the concentration, which in turn sets how many insulin units correspond to a given microgram target — a calculation that is easy to get wrong by an order of magnitude. Our peptide reconstitution calculator handles that arithmetic, but a clean conversion does not make an unvalidated dose safe. The math tells you what is in the syringe; it does not tell you it belongs in your body.

Topical versus injected, in one line

The split is clean enough to memorize: topical GHK-Cu is a long-established cosmetic with defined low concentrations and a reasonable surface-use safety record;^[1] injected GHK-Cu is an unregulated research chemical with no validated dose, scant human data, and a built-in copper-overload hazard.^[5] The evidence that supports a serum does not transfer to a syringe.

The honest bottom line

There is no FDA-approved GHK-Cu dose because there is no FDA-approved GHK-Cu product. The defensible use is topical, at the modest concentrations cosmetic formulations have long used, for modest cosmetic ends.^[1][3] The injectable “anti-aging” protocols rest on preclinical biology and forum convention, carry a real copper-toxicity risk, and have no human dosing evidence behind them.^[4][5] If anyone is weighing systemic use, that decision — and any number attached to it — belongs with a clinician who can actually monitor copper status, not with a screenshot of someone’s protocol.